Akèy › Lukemi lenfositè kwonik › Minnesota › Rochester
Etid klinik pou Lukemi lenfositè kwonik nan Rochester, MN
19 etid pou Lukemi lenfositè kwonik ap chèche patisipan nan sit nan ak bò kote Rochester (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Ap rekriteFaz 2
- Mayo Clinic in Rochester, Rochester
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Ap rekriteFaz 1/2
- Research Site, Rochester
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Ap rekriteFaz 3
- Mayo Clinic Rochester, Rochester
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Ap rekriteFaz 1/2
- Mayo Clinic Rochester, Rochester
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Ap rekriteFaz 3
- Mayo Clinic Rochester, Rochester
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Ap rekriteFaz 3
- Mayo Clinic Rochester, Rochester
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Ap rekriteFaz 1
- Mayo Clinic Rochester, Rochester
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Ap rekriteFaz 1/2
- Mayo Clinic, Rochester
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Ap rekriteFaz 1/2
- Mayo Clinic, Clinical Trials Referral Office, Rochester
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Ap rekriteFaz 2
- Mayo Clinic, Rochester
CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
Ap rekriteFaz 1
- Mayo Clinic in Rochester, Rochester
The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients
Ap rekriteVolontè an sante akeyi
- Mayo Clinic in Rochester, Rochester
Hematopoiesis in MBL and CLL Versus Healthy Age-Matched Control Subjects
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Mayo Clinic in Rochester, Rochester
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Ap rekriteFaz 2
- Mayo Clinic in Rochester, Rochester
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Ap rekriteFaz 4
- Mayo Clinic- Minnesota, Rochester
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Ap rekriteFaz 4
- Mayo Clinic- Minnesota, Rochester
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
Ap rekriteEtid obsèvasyon
- Mayo Clinic in Rochester, Rochester
Family Study of Lymphoproliferative Disorders
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Mayo Clinic, Rochester
Q702 for the Treatment of Patients With Hematologic Malignancies
Ap rekriteFaz 1
- Mayo Clinic in Rochester, Rochester
Etid Lukemi lenfositè kwonik nan lòt vil
- Boston, MA31 etid
- Columbus, OH28 etid
- Durham, NC27 etid
- Washington, DC22 etid
- Seattle, WA20 etid
- New York City, NY18 etid
- Houston, TX17 etid
- Baldwin Park, CA16 etid
- Milwaukee, WI15 etid
- Cincinnati, OH14 etid
- Chicago, IL14 etid
- Nashville, TN13 etid
Lòt etid nan Rochester
- Kansè nan tete42 etid
- Kansè Poumon ki pa ti selil37 etid
- Kansè Metastatik31 etid
- Kansè (tout kalite)30 etid
- Kansè kolorektal29 etid
- Kansè ovè29 etid
- Myelom Miltip24 etid
- Kansè pwostat22 etid
- Ensifizyans kadyak22 etid
- Kansè pankreyas22 etid
- Kansè poumon20 etid
- Kansè Endomèt20 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.